A Phase 2 interventional study of Epoetin Alfa and Standard of care in Renal Failure , Chronic and Anemia, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-05-13.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic — 1 open to participants now, 1 under way, none of them phase 3. Epoetin Alfa · Renal Insufficiency, Chronic.
Among the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, this one is the 13th largest by enrollment, is one of 3 that started in 2006, is one of 5 in phase 2, and was the 5th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →1 of the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic is open now, in 1 country. Recruiting first, the newest first:
Services Hospital, Lahore · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2006.
This study's enrollment of 157 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 157 across the 25 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Pharmaceutical Research & Development, L.L.C., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
Johnson & Johnson has 9 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
1 of the studies testing Epoetin Alfa in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07755683Services Hospital, LahoreEffect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to show that giving PROCRIT (Epoetin alfa) every 2 weeks to increase the hemoglobin (Hb) level and then to adjust the PROCRIT (Epoetin alfa) dose every 4 weeks (Q4W) to maintain Hb levels, is safe and effective in patients with anemia from Chronic Kidney Disease (CKD), not on dialysis, who reside in long-term care facilities. In this study the frequency of PROCRIT (Epoetin alfa) dosing is under investigation.
PROCRIT (Epoetin alfa) is a brand of recombinant human erythropoietin (rHuEPO). Erythropoietin is a hormone produced in the kidney. Its function is to stimulate the production of red blood cells in the bone marrow. Many patients with Chronic Kidney Disease (CKD) do not produce enough erythropoietin and thus develop anemia (a reduction in red blood cell levels). This can cause them to feel tired.
PROCRIT (Epoetin alfa) is approved by the United States Food and Drug Administration (FDA) for the treatment of anemia (low red blood cell count) in patients with CKD (not on dialysis). The approved dosing frequency for PROCRIT (Epoetin alfa) in patients with CKD is one injection three times per week. Although PROCRIT (Epoetin alfa) is approved by the FDA for the treatment of certain types of anemia at different dosing schedules, the dosing schedules that will be used in this study are investigational in CKD. An investigational use is one that is currently not approved by the FDA.
This is an open-label, randomized (patients are assigned different treatments based on chance), multi-center, controlled study of patients with anemia of Chronic Kidney Disease (CKD), not on dialysis, who reside in long-term care facilities. Approximately 156 patients with CKD, not on dialysis, who have not received an erythropoietin receptor agonist (a drug that stimulates red blood cell production) for eight weeks immediately prior to screening (Week -1) and who have a hemoglobin (Hb, a measure of the number of red blood cells), less than 11 g/dL at screening will be eligible to participate. Patients will be evaluated for eligibility during a one-week screening phase. Eligible patients will be randomized in a 3:1 ratio to a PROCRIT (Epoetin alfa) group or to the control group for a period of 26 weeks. Randomization is done through a computer that randomly assigns the subject by chance (like rolling dice) to one of two groups (No one can choose the group to which they will be assigned.). They will have a 3 to 1 chance of being assigned to Group 1 versus Group 2, which means that out of every 4 patients entering the study 3 will receive PROCRIT (Epoetin alfa) and 1 will not.
Group 1 -will receive PROCRIT (Epoetin alfa) 20,000 Units (U) every 2 weeks until the hemoglobin reaches 11.0 g/dL or higher and remains at this level for two measurements in a row. At Week 6 or thereafter, the 20,000 Unit dose may be adjusted upward or downward as required to obtain the two consecutive hemoglobin measurements. Once the two consecutive measurements have been achieved, PROCRIT (Epoetin alfa) will be given every 4 weeks (Q4W) at double the previous dose to obtain a target hemoglobin of up to 12.0 g/dL. There will be no conversion to Q4W before Week 6 or after Week 18. If the hemoglobin drops, patients may go back to receiving PROCRIT (Epoetin alfa) every 2-weeks. If the hemoglobin rises above 12.0 g/dL, patients will not receive another dose of PROCRIT (Epoetin alfa) until the Hg level is below 12.0 g/dL. If the hemoglobin rises rapidly, patients will not receive another dose of PROCRIT (Epoetin alfa) until the rise is 1 g/dL or less in a 2-week period. The maximum amount of PROCRIT (Epoetin alfa) that this group can receive is 60,000 Units over a 4-week period. All doses of PROCRIT (Epoetin alfa) are injected under the skin (subcutaneous).
Group 2 - will not receive any PROCRIT (Epoetin alfa). This group will continue to receive the care that they are now receiving from their physician and the physician will review all lab results.
Since a lack of iron could interfere with the ability of patients to make red blood cells, patients in both groups will have iron levels checked at the screening visit and during the study. Based on the results of iron tests, the study doctor may prescribe an oral (by mouth) or intravenous (injection) iron supplement during the study. If the need for iron supplementation is determined, patients will receive iron supplementation no matter which group they are in.
Every two weeks a study visit will be performed. At each visit, blood pressure and heart rate will be checked, and blood will be drawn for all patients and sent to the central laboratory for complete blood count (CBC). The Hb by CBC will be used for efficacy analysis ( to measure the effectiveness of the study drug in increasing the hemoglobin level). Hb testing by HemoCue will be performed every two weeks on-site for PROCRIT (Epoetin alfa) group patients, for the purpose of real-time dosing decisions. (HemoCue is the brand name of a portable hemoglobin test that uses a drop of blood to obtain immediate hemoglobin measurements). PROCRIT (Epoetin alfa) will be administered at a dose based on the HemoCue Hb measurement. Full hematology panel, serum chemistry, and iron status will be assessed at intervals throughout the study by a central laboratory. The number of units of packed red blood cells (PRBC) transfused, pre-transfusion Hb level, and the reasons for transfusion will be collected. Hemoglobin response will also be measured. A patient exhibiting a hemoglobin response will have two consecutive Hb measurements at least 1 g/dL greater than baseline any time during the study or have two consecutive Hb measurements >= 11.0 g/dL at any time during the study. Falls, activities of daily living (ADLs), and mobility will be assessed during the study. Clinical laboratory results, blood pressure and heart rate, and the incidence and severity of adverse events will be monitored during the study.
The study hypothesis is that the mean Hb change from baseline to the end of study will be significantly higher in the PROCRIT (Epoetin alfa) group over the control group. Group 1 patients will receive a maximum of 13 doses of PROCRIT (Epoetin alfa) by subcutaneous injection (under the skin) for up to 26 weeks. Dosage is based on the hemoglobin measurement done at each visit. Doses will be started at an every 2-week interval and may be increased to every four weeks. The maximum dose that can be given is 60,000 Units of PROCRIT (Epoetin alfa) over a 4-week period. Any PROCRIT (Epoetin alfa) dose over 40,000 Units will be administered in two separate injections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Epoetin Alfa
Standard treatment of anemia excluding use of erythropoetin stimulating agents (ESAs).
Other: Standard of care
Epoetin alfa administered at 20,000 IU subcutaneously every 2 weeks for a period of 26 weeks
Also known as: Standard treatment of anemia excluding use of erythropoetin stimulating agents (ESAs).
Mean Change in Hemoglobin Level From Baseline to the End of Study (26 Weeks)
Time frame: Week 0 to Week 26
The Number of Patients Achieved a Hemoglobin Response.
Hemoglobin reponse was defined as 2 consecutive hemoglobin measurements at least 1.0 g/dL above baseline or 2 consecutive hemoglobin measurements at least 11.0 g/dL
Time frame: Week 0 to Week 26
Time to Hemoglobin Response
Time to hemoglobin reponse was defined as the time between individual treatment start date and the first of 2 consecutive hemoglobin measurements at least 1.0 g/dL above baseline or 2 consecutive hemoglobin measurements at least 11.0 g/dL. Note: Upper 95% confidence limit for the Standard of Care Group was not estimable because an insufficient number of participates reached the event at the final time point for assessment.
Time frame: Week 0 to Week 26
| Milestone | Standard of Care | PROCRIT (Epoetin Alfa) |
|---|---|---|
| Started | 39 | 118 |
| Completed | 29 | 91 |
| Not completed | 10 | 27 |
| Withdrew: Adverse event | 2 | 5 |
| Withdrew: Death | 2 | 8 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 4 | 3 |
| Withdrew: Withdrawal by subject | 1 | 7 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| g/dL | Standard of Care | PROCRIT (Epoetin Alfa) |
|---|---|---|
| Mean Change in Hemoglobin Level From Baseline to the End of Study (26 Weeks) | 0.3 ± 1.3 | 0.9 ± 1.0 |
Hemoglobin reponse was defined as 2 consecutive hemoglobin measurements at least 1.0 g/dL above baseline or 2 consecutive hemoglobin measurements at least 11.0 g/dL
| participants | Standard of Care | PROCRIT (Epoetin Alfa) |
|---|---|---|
| The Number of Patients Achieved a Hemoglobin Response. | 21 | 97 |
Time to hemoglobin reponse was defined as the time between individual treatment start date and the first of 2 consecutive hemoglobin measurements at least 1.0 g/dL above baseline or 2 consecutive hemoglobin measurements at least 11.0 g/dL. Note: Upper 95% confidence limit for the Standard of Care Group was not estimable because an insufficient number of participates reached the event at the final time point for assessment.
| Days | Standard of Care | PROCRIT (Epoetin Alfa) |
|---|---|---|
| Time to Hemoglobin Response | 114 (43 to NA) | 41 (29 to 43) |
Collected over 26 weeks or early withdraw. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard of Care | — | 14/39 (35.9%) | 34/39 (87.2%) |
| PROCRIT (Epoetin Alfa) | — | 39/118 (33.1%) | 99/118 (83.9%) |
| Event | Standard of Care | PROCRIT (Epoetin Alfa) |
|---|---|---|
| Acute Myocardial InfarctionCardiac disorders | 3/39 | 1/118 |
| Renal FailureRenal and urinary disorders | 3/39 | 0/118 |
| Cardiac Failure CongestiveCardiac disorders | 2/39 | 4/118 |
| UrosepsisInfections and infestations | 2/39 | 0/118 |
| PneumoniaInfections and infestations | 1/39 | 5/118 |
| Renal Failure AcuteRenal and urinary disorders | 0/39 | 5/118 |
| Urinary Tract InfectionInfections and infestations | 0/39 | 4/118 |
| BradycardiaCardiac disorders | 1/39 | 0/118 |
| GastroenteritisInfections and infestations | 1/39 | 1/118 |
| OesteomyelitisInfections and infestations | 1/39 | 0/118 |
| Event | Standard of Care | PROCRIT (Epoetin Alfa) |
|---|---|---|
| Urinary Tract InfectionInfections and infestations | 9/39 | 21/118 |
| VomitingGastrointestinal disorders | 8/39 | 22/118 |
| Skin LacerationInjury, poisoning and procedural complications | 6/39 | 24/118 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/39 | 20/118 |
| DiarrhoeaGastrointestinal disorders | 6/39 | 19/118 |
| ContusionInjury, poisoning and procedural complications | 6/39 | 17/118 |
| Oedema PeripheralGeneral disorders | 5/39 | 13/118 |
| HyperkalaemiaMetabolism and nutrition disorders | 5/39 | 2/118 |
| ConstipationGastrointestinal disorders | 4/39 | 6/118 |
| ExcoriationInjury, poisoning and procedural complications | 4/39 | 8/118 |
| Age, Categorical(Participants) | Standard of Care | PROCRIT (Epoetin Alfa) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 4 | 6 |
| >=65 years | 37 | 114 | 151 |
| Age Continuous(Years) | Standard of Care | PROCRIT (Epoetin Alfa) | Total |
|---|---|---|---|
| Mean | 84.4 ± 10.9 | 84.1 ± 9.2 | 84.1 ± 9.6 |
| Sex: Female, Male(Participants) | Standard of Care | PROCRIT (Epoetin Alfa) | Total |
|---|---|---|---|
| Female | 33 | 90 | 123 |
| Male | 6 | 28 | 34 |
No study locations are listed for this record.
The record gives a start of Jul 2006, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa
Renal Insufficiency, Chronic →
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →